Abstract:The past year has offered significant advancements in the field of non–small cell lung cancer (NSCLC), both in the early and advanced disease settings. The identification of guideline‐recommended actionable targets has provided the foundation for developing multiple new therapeutic agents. There has been a focus on developing drugs designed to overcome acquired resistance, a limitation of tyrosine kinase inhibitor–based therapy in lung cancer. In addition, there is an emerging trend toward combination therapies for patients in the first‐line setting with the goal of preventing or delaying resistance. Another promising area of development has been the use of antibody–drug conjugates, where there are the initial reports of central nervous system efficacy and activity in patients with genomic alterations. Over the past year, numerous publications and presentations have highlighted multiple therapeutic advances, offering new treatment options for patients with NSCLC. The focus of this review is to summarize the most impactful findings, emphasizing their significance in the evolving treatment landscape for NSCLC. Several landmark trials in lung cancer with practice‐changing clinical implications have been presented and published in 2023. This article reviews a selection of these trials as they relate to early and advanced‐stage oncogene‐driven lung cancer. The ADAURA and ALINA trials, in which targeted therapy given in the adjuvant setting has demonstrated improved clinical outcomes, are reviewed. In the advanced‐stage setting, recent trials in the context of specific oncogene drivers are reviewed, including EGFR, ALK, ROS1, RET, ERBB2 (HER2), BRAF, MET exon 14 skipping (METex14), and KRAS alterations. Also discussed are the results of several trials that have evaluated the use of combination therapies and resistance‐mechanism agnostic treatment strategies. Plain Language Summary Targeted therapy plays an important role for patients with early and advanced‐stage non–small cell lung cancer carrying specific genetic alterations. New strategies that combine multiple therapies are now being studied in randomized clinical trials, with the goal of enhancing the effectiveness of targeted therapy for patients with advanced lung cancer.

Lung Cancer Treatment Advances in 2022

Scientific Advances in Lung Cancer 2015

Update 2020: Management of Non-Small Cell Lung Cancer

Update 2021: Management of Small Cell Lung Cancer

Top advances of the year: Targeted therapy for lung cancer

Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)

Advances in Clinical Trials of Targeted Therapy and Immunotherapy of Lung Cancer in 2018

[Advances in Surgical Treatment of Early Stage Non-small Cell Lung Cancer].

Research advances in non-small-cell lung cancerin ASCO

Medical Treatment of Advanced Non-Small Cell Lung Cancer: Progress in 2014

Recent advances in non-small cell lung cancer targeted therapy; an update review

Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022

New promises and challenges in the treatment of advanced non-small-cell lung cancer

Lung cancer

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Advances in Non-Small Cell Lung Cancer (NSCLC) Treatment—A Paradigm Shift in Oncology

Advances in radiotherapy techniques and delivery for non-small cell lung cancer: benefits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Advances of Treatment of Small Cell Lung Cancer in 2011 American Society of Clinical Oncology Annual Meeting